Clinical Trials Directory

Trials / Completed

CompletedNCT05305391

Low-grade Inflammation and Gut Symptoms From A2 and Hydrolyses A1 Milk

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
37 (actual)
Sponsor
University of Turku · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The aim of this study is to reveal how different forms of milk casein, lactose and moderate breakdown of proteins affect the symptoms that may arise from milk and markers of inflammation in volunteers receiving symptoms from milk. Research hypotheses are: 1) Protein hydrolyzed milk is as tolerated or better tolerated than A2 milk, and 2) Lactose is the main causative agent of stomach symptoms in milk-sensitive individuals.

Conditions

Interventions

TypeNameDescription
OTHERDietary interventionThe arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.

Timeline

Start date
2022-05-18
Primary completion
2023-03-03
Completion
2023-03-03
First posted
2022-03-31
Last updated
2023-03-21

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT05305391. Inclusion in this directory is not an endorsement.

Low-grade Inflammation and Gut Symptoms From A2 and Hydrolyses A1 Milk (NCT05305391) · Clinical Trials Directory